Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease
A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
A Novel Non-Bile Acid FXR Agonist EDP-305 Potently Suppresses Liver Injury and Fibrosis without Worsening of Ductular Reaction
The Farnesoid X Receptor Agonist EDP-305 Reduces Interstitial Renal Fibrosis in a Mouse Model of Unilateral Ureteral Obstruction
Decreases in Serum 7-alpha-Hydroxy-4-Cholesten-3-One (C4) Correlate Well with Anti-Fibrotic Efficacy of EDP-305 in Nonalcoholic Steatohepatitis (NASH) and Biliary Fibrosis Animal Models
A Phase 2 Dose Ranging, Randomized, Double-blind and Placebo-Controlled Study of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
Tissue distribution of EDP-305, a highly selective and potent farnesoid X receptor (FXR) agonist, in preclinical species
EDP-305, a Highly Selective and Potent FXR Agonist, Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity Score (NAS) in Two Murine Models of NASH